RFC1 Natural History Study
Launched by PROF. DR. MATTHIS SYNOFZIK · Dec 14, 2021
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
The RFC1 Natural History Study is an international research project that aims to better understand a specific type of ataxia, which is a condition that affects coordination and balance. This study will look at how the condition develops over time and identify potential tools, like digital tests and imaging scans, that could help doctors diagnose it and measure how well treatments work in the future. The study is currently recruiting participants, and it welcomes individuals aged 65 and older who have a confirmed genetic diagnosis related to RFC1 repeat expansions. Additionally, healthy volunteers without any neurological or psychiatric conditions can join as control participants.
If you choose to participate, you can expect to undergo various assessments and tests that will help researchers gather important information about the disease. It's essential that participants are able to provide informed consent, meaning they agree to join the study after understanding what it involves. This study is crucial for advancing knowledge about ataxia and could pave the way for better diagnoses and treatments in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • RFC1: genetic diagnosis of bi-allelic pathogenic repeat expansions in RFC1
- • Unrelated healthy controls: no signs or history of neurological or psychiatric disease AND
- • Written informed consent AND
- • Participants are willing and able to comply with study procedures
- Exclusion Criteria:
- • RFC1: Missing informed consent
- • Controls: evidence of neuropathy, neurodegenerative disease, or movement disorder; inability to give informed consent
About Prof. Dr. Matthis Synofzik
Prof. Dr. Matthis Synofzik is a distinguished clinical trial sponsor renowned for his expertise in neurology and neurodegenerative disorders. With a robust background in clinical research and a commitment to advancing therapeutic strategies, he leads innovative studies aimed at improving patient outcomes in complex neurological conditions. His interdisciplinary approach fosters collaboration among researchers, clinicians, and patients, ensuring that clinical trials are not only scientifically rigorous but also ethically sound and patient-centered. Prof. Synofzik's dedication to excellence in research is reflected in his numerous publications and contributions to the field, positioning him as a key figure in the advancement of neurological healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pisa, , Italy
Tübingen, Baden Württemberg, Germany
Melbourne, Victoria, Australia
São Paulo, State Of São Paulo, Brazil
Strasbourg, , France
Bonn, Nordrhein Westfalen, Germany
Lübeck, Schleswig Holstein, Germany
Napoli, , Italy
Auckland, , New Zealand
Istanbul, , Turkey
Tübingen, , Germany
São Paulo, , Brazil
Patients applied
Trial Officials
Matthis Synofzik, Prof. Dr.
Principal Investigator
University Hospital Tübingen
Andreas Traschütz, Dr. Dr.
Principal Investigator
University Hospital Tübingen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials